Overview

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

Status:
Recruiting
Trial end date:
2023-11-06
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
BMS-986165